Thank you for sharing your concerns, AlCp. However, I have to disagree with your assessment of PainChek's potential. PainChek's technology has already shown to be highly effective in the healthcare industry, and the company has made significant progress in commercializing its product in various regions globally.
Furthermore, the partnership with Dementia Australia amongst many others, and the successful launch of PainChek Universal are both significant milestones that demonstrate the growing demand for PainChek's technology.
While it is true that some healthcare providers may still prefer the manual process of the APS assessment, it is important to note that PainChek's technology provides an objective and digitalized approach that is highly accurate and efficient. The fact that PainChek is already being used by numerous healthcare providers and receiving positive feedback from users is a testament to its potential.
Overall, I believe that PainChek is a compelling investment opportunity at its current price, and I am optimistic about its future growth prospects.
PCK Price at posting:
2.7¢ Sentiment: Buy Disclosure: Not Held
